CSL Ltd Annual Report 2021

Delivering innovative solutions to unprecedented challenges CSL’s long-term effort to create an enterprise-wide culture of innovation delivered results in the reporting year with new and unique approaches to address hurdles imposed by the global pandemic. Drawing on our digital expertise, the company was quick to implement strategies to keep employees connected amid travel restrictions and office closures. We also found new ways to collaborate, share knowledge and continue to develop and deliver our lifesaving therapies to patients. Beyond the pandemic, CSL will continue its ongoing digital transformation by developing new ways to connect patients to researchers and each other through online initiatives that demonstrate the company’s patient focus. These new ways to work, collaborate and connect have CSL well-positioned to further drive innovation as we progress to our 2030 strategy. Connecting organ transplant candidates and recipients People who share the same health problems often look for each other online. TransplantLyfe, a new online platform for transplant candidates and recipients, makes those supportive check-ins a little easier. TransplantLyfe.com, created by Lyfebulb in collaboration with CSL Behring, offers resources, a find-a-friend option and forums. The platform is designed to address the emotional needs of transplant recipients – something that can be overlooked amid the highly complex medical journey. Recipients of a donated organ experience complex emotions post-surgery and are at risk of anxiety and depression. Relatively few people receive an organ transplant each year, so it’s hard for people to meet someone local who’s going through the same thing. The COVID-19 pandemic created another barrier, making TransplantLyfe a timely initiative. Power of real-world evidence The use of real-world evidence (RWE) is increasingly important amongst policy makers, decisionmakers and purchasers. CSL Behring leverages RWE inmany facets of its business – from identifying disease burden and unmet medical needs; determining whether certain conditions meet the criteria for orphan drug designation; contextualising the observed rates of adverse reactions in ongoing clinical trials; through to post-approval assessment of the safety of marketed products. Seqirus continues to generate extensive RWE in support of our seasonal influenza vaccines to evaluate vaccine effectiveness on an annual basis and provide an ever-growing dataset to assess real-world outcomes, offering insights from larger, more diverse patient populations and healthcare settings. In the context of the COVID-19 pandemic and the simultaneous distribution of COVID-19 vaccines, gathering RWE on the performance of our vaccines is evenmore important. Inviting clinical trial participation through patient-facing portal Clinical trials sit at the heart of the process for developing and delivering lifesaving medicines for patients. With that inmind, CSL has broadened its efforts to recruit and interact with clinical trial participants by developing the Electronic Portal Exchange or EPEX platform. EPEX includes a patient-facing website that offers information about CSL’s ongoing clinical trials, education on the clinical trial process and stories of interest about patients who have taken part in a clinical trial. The platformwill also host a secured access participant engagement portal that allows CSL to provide information and interact with study participants from the screening process to the completion of their clinical trial participation. Augmenting reality to overcome travel challenges As part of CSL’s ongoing digital transformation, we have been exploring the potential use of Augmented Reality (AR) across numerous business functions. Amid pandemic-related travel restrictions, a new usage of AR was quickly applied at our Quality Control site in Amsterdam. The Amsterdam site was busy getting up to speed in preparation for BREXIT. Through the use of AR technology, UK-basedmembers of the Quality Control team were able to virtually visit the Amsterdam laboratory to train colleagues and transfer knowledge. Employees in Amsterdam donned AR smart glasses and the team in Liverpool, UK demonstrated the necessary processes. The use of these AR headsets at the AmsterdamQuality Control laboratory continue to solve business challenges. As pandemic-related restrictions ease, using this technology enables our business colleagues and suppliers to work more flexibly, whilst reducing CSL’s carbon footprint. CSL Limited Annual Report 2020/21 31